Roivant Sciences (87S) Price & Analysis

2 Followers

87S Stock Chart & Stats

€28.93

-€0.81(-2.70%)

At close: Jul 29 4:00 PM EDT

€28.93

-€0.81(-2.70%)

Day’s Range― - ―

52-Week Range€15.01 - €35.82

Previous CloseN/A

Volume0.00

Average Volume (3M)24.00

Market Cap

€22.46B

Enterprise Value€22.46B

Total Cash (Recent Filing)€3.84B

Total Debt (Recent Filing)€107.15M

Price to Earnings (P/E)―

Beta0.31

Next Earnings

Nov 09, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding722,323,000

10 Day Avg. Volume0

30 Day Avg. Volume24

Financial Highlights & Ratios

PEG Ratio-0.81

Price to Book (P/B)4.25

Price to Sales (P/S)2326.88

P/FCF Ratio-25.34

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€42.56

Price Target Upside47.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-1.23

Revenue Forecast (FY)€46.39M

Bulls Say, Bears Say

Bulls Say

Dermatomyositis ApprovalFDA approval gives Roivant an established commercial product in an underserved rare disease, with first-mover positioning and a differentiated targeted therapy. The label’s symptom and steroid-sparing benefits may support durable adoption and create a platform for expansion into additional indications.

Uveitis Pipeline ValidationPositive Phase 3 results across efficacy, steroid-free disease control, visual outcomes, and key subgroups materially strengthen brepocitinib’s development profile. A planned supplemental filing could broaden the commercial opportunity and diversify growth beyond dermatomyositis.

Balance Sheet FlexibilityVery low leverage and a sizable equity base provide financial flexibility to fund clinical programs, regulatory filings, and launches without relying heavily on debt. This capacity is strategically valuable for a development-stage biotechnology company with several programs advancing simultaneously.

Bears Say

Persistent Cash BurnLarge recurring operating and free-cash-flow deficits mean Roivant is consuming substantial capital while advancing its pipeline. Continued burn can reduce the duration of its financial runway and may constrain future investment or require additional financing if commercialization does not scale quickly.

Weak Profitability And Revenue TrendThe company has not yet converted its research and development base into dependable earnings, while declining revenue and significant operating losses reduce financial predictability. Sustained cost growth ahead of product adoption could keep returns on the substantial capital base negative.

JAK Safety And Uptake RiskClass-wide JAK safety perceptions may limit prescribing, reimbursement, or patient acceptance even with favorable product-specific trial results. This creates a durable commercialization risk for LISRAYA, potentially slowing penetration and reducing the revenue contribution expected from its first launch.

Roivant Sciences News

Roivant Sciences price target raised to $62 from $55 at TD Cowen

TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $62 from $55 and keeps a...

2d ago

ROIV

Midday Fly By: SpaceX reports Q3 beat, will consider Tesla merger

The major averages were higher near noon, supported by upbeat results from SpaceX and Super Micro Computer that...

2d ago

Roivant, Priovant report CLARITY-1 and CLARITY-2 trials meet primary endpoint

Roivant and Priovant Therapeutics announced results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis, or...

2d ago

ROIV

Chardan biotech/pharma analysts hold analyst/industry conference call

Biotech & Pharma Analysts discuss pulmonary arterial hypertension (PAH) and PAH associated with interstitial lung disease (PH-ILD) (relevant...

10d ago

IKT

GOSS

Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences

Citi analyst Samantha Semenkow added an “upside 90-day catalyst watch” on Roivant Sciences (ROIV) while keeping a Buy...

11d ago

ROIV

Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Roivant Sciences (ROIV) to Peer Perform from Outperform with no price target The stock profile...

11d ago

ROIV

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week...

30d ago

IMVT

ROIV

Roivant reports strong Phase 3 data in uveitis

Roivant Sciences ( ($ROIV) ) has issued an update. On October 21, 2026, Roivant and its subsidiary Priovant...

2d ago

ROIV

Roivant Sciences price target raised to $41 from $37.50 at BofA

BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and...

1M ago

IMVT

ROIV

Roivant announces trial of IMVT-1402 did not reach statistical significance

Roivant announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous...

1M ago

ROIV

Roivant Shareholders Approve Directors and Governance Matters

An update from Roivant Sciences ( ($ROIV) ) is now available. On September 16, 2026, Roivant Sciences Ltd....

1M ago

ROIV

Roivant Sciences initiated with a Buy at Stifel

Stifel initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $51 price target The company offers...

1M ago

ROIV

Roivant advances mosliciguat with positive Phase 2 results

An announcement from Roivant Sciences ( ($ROIV) ) is now available. On September 8, 2026, Roivant reported positive...

2M ago

ROIV

Lisraya Pricing Upside and Measured Launch Drive Modest Roivant Target Increase to $37.50, Supporting Hold Rating Amid Balanced Risk/Reward

Roivant Sciences, the Healthcare sector company, was revisited by a Wall Street analyst on August 28. Analyst Chi...

2M ago

ROIV

87S FAQ

What was Roivant Sciences’s price range in the past 12 months?

Roivant Sciences lowest stock price was €15.01 and its highest was €35.82 in the past 12 months.

What is Roivant Sciences’s market cap?

Roivant Sciences’s market cap is €22.46B.

When is Roivant Sciences’s upcoming earnings report date?

Roivant Sciences’s upcoming earnings report date is Nov 09, 2026 which is in 17 days.

How were Roivant Sciences’s earnings last quarter?

Roivant Sciences released its earnings results on Aug 06, 2026. The company reported -€0.299 earnings per share for the quarter, missing the consensus estimate of -€0.268 by -€0.031.

Is Roivant Sciences overvalued?

According to Wall Street analysts Roivant Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences pay dividends?

Roivant Sciences does not currently pay dividends.

What is Roivant Sciences’s EPS estimate?

Roivant Sciences’s EPS estimate is -0.33.

How many shares outstanding does Roivant Sciences have?

Roivant Sciences has 722,323,000 shares outstanding.

What happened to Roivant Sciences’s price movement after its last earnings report?

Roivant Sciences reported an EPS of -€0.299 in its last earnings report, missing expectations of -€0.268. Following the earnings report the stock price went down -0.101%.

Which hedge fund is a major shareholder of Roivant Sciences?

Currently, no hedge funds are holding shares in DE:87S

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Roivant Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-6.12%

Trailing 12-Months

Asset Growth

5.44%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Roivant Sciences (87S) Earnings & Revenues

Historic Earnings Reports

87S Company Deck

87S Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.View all DE:87S earnings summaries

87S Stock 12 Month Forecast

Average Price Target

€42.56

▲(47.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","56":"€56","22.25":"€22.3","33.5":"€33.5","44.75":"€44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.2016907,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€55.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.558722829999994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.613994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,22.25,33.5,44.75,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,33.572437746153845,35.374875492307694,37.17731323846154,38.979750984615386,40.78218873076923,42.58462647692308,44.38706422307692,46.18950196923077,47.99193971538462,49.79437746153846,51.5968152076923,53.39925295384616,{"y":55.2016907,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,32.59990175615385,33.42980351230769,34.25970526846154,35.08960702461538,35.91950878076923,36.74941053692307,37.57931229307692,38.40921404923076,39.239115805384614,40.06901756153846,40.898919317692304,41.72882107384615,{"y":42.558722829999994,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,32.06569184615385,32.36138369230769,32.65707553846154,32.952767384615385,33.24845923076923,33.54415107692308,33.83984292307692,34.135534769230766,34.43122661538462,34.72691846153846,35.022610307692304,35.318302153846155,{"y":35.613994,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.455,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.165,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.79,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.03,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.77,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >